Depressive DisordersMedicinal Chemistry & Drug Development

Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity

This chemistry paper (2022) simulates the docking of 75 million molecules (tetrahydropyridines, THP) on the serotonin 2a (5-HT2a) receptor. The initial screening led to 17 molecules that were further refined down to two molecules ((R)-69 & (R)-70). These two had antidepressant effects (in mice) but didn't show (acute) psychoactive activity (head-twitch response, change in movement).

Authors

  • John McCorvy
  • Bryan Roth
  • Kuglae Kim

Published

Nature
individual Study

Abstract

There is considerable interest in screening ultralarge chemical libraries for ligand discovery, both empirically and computationally. Efforts have focused on readily synthesizable molecules, inevitably leaving many chemotypes unexplored. Here we investigate structure-based docking of a bespoke virtual library of tetrahydropyridines-a scaffold that is poorly sampled by a general billion-molecule virtual library but is well suited to many aminergic G-protein-coupled receptors. Using three inputs, each with diverse available derivatives, a one pot C-H alkenylation, electrocyclization and reduction provides the tetrahydropyridine core with up to six sites of derivatization. Docking a virtual library of 75 million tetrahydropyridines against a model of the serotonin 5-HT2A receptor (5-HT2AR) led to the synthesis and testing of 17 initial molecules. Four of these molecules had low-micromolar activities against either the 5-HT2A or the 5-HT2B receptors. Structure-based optimization led to the 5-HT2AR agonists (R)-69 and (R)-70, with half-maximal effective concentration values of 41 nM and 110 nM, respectively, and unusual signalling kinetics that differ from psychedelic 5-HT2AR agonists. Cryo-electron microscopy structural analysis confirmed the predicted binding mode to 5-HT2AR. The favourable physical properties of these new agonists conferred high brain permeability, enabling mouse behavioural assays. Notably, neither had psychedelic activity, in contrast to classic 5-HT2AR agonists, whereas both had potent antidepressant activity in mouse models and had the same efficacy as antidepressants such as fluoxetine at as low as 1/40th of the dose. Prospects for using bespoke virtual libraries to sample pharmacologically relevant chemical space will be considered.

Available with Blossom Pro

Research Summary of 'Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity'

Introduction

Earlier work has shown that ultralarge virtual and DNA-encoded libraries can expand the chemical space sampled in ligand discovery, but many chemotypes remain absent or under-represented in these general-purpose sets. Kaplan and colleagues note that six-membered nitrogen heterocycles such as piperidines and pyridines are common in approved drugs, whereas tetrahydropyridines (THPs) — midway in saturation between pyridines and piperidines — are comparatively rare in make-on-demand libraries despite possessing desirable features (basic nitrogen, three-dimensionality and multiple sites for substitution). The authors developed convergent synthetic routes that give THP cores with up to six points of derivatisation, enabling the construction of a bespoke virtual library around this scaffold. This study set out to test whether a focused, synthetically tractable virtual library of THPs could be efficiently docked to identify new aminergic GPCR ligands, using the serotonin 5-HT2A receptor (5-HT2A R) as a therapeutically relevant test case. The aims were to (1) build and screen an ultralarge bespoke THP library by structure-based docking, (2) synthesise and optimise docking-prioritised hits, (3) determine receptor binding modes structurally, and (4) evaluate pharmacology and in vivo behavioural effects, with a particular interest in agonists that might retain antidepressant activity without classical psychedelic effects.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

  • Study Type
    individual
  • Journal
  • Topics
  • Authors
  • APA Citation

    Kaplan, A. L., Confair, D. N., Kim, K., Barros-Álvarez, X., Rodriguiz, R. M., Yang, Y., Kweon, O. S., Che, T., McCorvy, J. D., Kamber, D. N., Phelan, J. P., Martins, L. C., Pogorelov, V. M., DiBerto, J. F., Slocum, S. T., Huang, X., Kumar, J. M., Robertson, M. J., Panova, O., . . . Ellman, J. A. (2022). Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature, 610(7932), 582-591. https://doi.org/10.1038/s41586-022-05258-z

References (10)

Papers cited by this study that are also in Blossom

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Crystal Structure of an LSD-Bound Human Serotonin Receptor

Wacker, D., Wang, S., Mccorvy, J. D. et al. · Cell (2017)

Psychedelics and the human receptorome

Ray, T. S. · PLOS ONE (2010)

265 cited
Structure-based discovery of nonhallucinogenic psychedelic analogs

Cao, D., Yu, J., Wang, H. et al. · Science (2022)

Psychedelic Psychiatry’s Brave New World

Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Cited By (16)

Papers in Blossom that reference this study

1 cited
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics

Jain, M. K., Gumpper, R. H., Slocum, S. T. et al. · Neuron (2025)

Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors

Shao, L-X,, Tan, D., Liao, C., Davoudian, P. A. et al. · Nature Communications (2025)

The structural diversity of psychedelic drug actions revealed

Gumpper, R. H., Jain, M. K., Kim, K. et al. · Nature Communications (2025)

AlphaFold2 structures guide prospective ligand discovery

Lyu, J., Kapolka, N., Gumpper, R. et al. · Science (2024)

Synthetic surprise as the foundation of the psychedelic experience

De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)

CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity

Madsen, M. K., Petersen, A. S., Stenbæk, D. S. et al. · Headache (2024)

36 cited
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)

45 cited
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

Show all 16 papers
Identification of 5-HT 2A Receptor Signaling Pathways Responsible for Psychedelic Potential

Wallach, J., Cao, A. B., Calkins, M. M. et al. · Biorxiv (2023)

Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)

Canalization and plasticity in psychopathology

Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines

Cameron, L. P., Patel, S. D., Vargas, M. V. et al. · ACS Chemical Neuroscience (2023)

86 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.